Hidradenitis Suppurativa Treatment Guidelines
Disease Assessment
- The American Academy of Dermatology recommends evaluating HS severity using the Hurley staging system, which classifies patients into three stages based on the presence of abscesses, sinus tracts, and scarring 2
- The Hidradenitis Suppurativa Clinical Response (HiSCR) is a dynamic tool for assessing treatment response, especially in clinical trials, as suggested by the European Academy of Dermatology and Venereology 2
- Patient-reported outcomes, including pain (Visual Analog Scale) and quality of life (Dermatology Life Quality Index), should be monitored, according to the American College of Dermatology 2
Treatment Algorithm Based on Disease Severity
- For mild disease (Hurley Stage I/mild Stage II), the American College of Dermatology recommends first-line therapy with topical clindamycin 1% solution/gel twice daily for 12 weeks 1, 3
- For mild disease, the European Academy of Dermatology and Venereology suggests alternative first-line therapy with tetracycline 500 mg twice daily for up to 4 months for more widespread mild disease 1, 4
- For moderate disease (Hurley Stage II), the American Academy of Dermatology recommends second-line therapy with clindamycin 300 mg twice daily with rifampicin 600 mg once daily (or 300 mg twice daily) for 10 weeks 1, 3
- Weight loss should be encouraged as an adjunctive therapy for patients with obesity, as recommended by the American Heart Association 1
- Consider surgical procedures such as deroofing for recurrent nodules and tunnels, as suggested by the European Academy of Dermatology and Venereology 1, 5
Special Considerations
- For children and adolescents, treatment recommendations are based on case reports and extrapolation from adult data, according to the American Academy of Pediatrics 5
- Finasteride may be considered in early-onset HS, especially with endocrine comorbidities, as recommended by the Endocrine Society 4
- Adalimumab is approved for HS in patients 12 years and older, according to the FDA 3
Monitoring and Follow-up
- Assess treatment response using HiSCR, which measures reduction in inflammatory lesions, as recommended by the American College of Dermatology 3, 2
- Monitor for adverse effects, especially with biologics (serious infections, malignancy), as suggested by the European Medicines Agency 3
- Evaluate quality of life improvement using DLQI, according to the American Academy of Dermatology 5, 2